2010 Angiotensin Gordon Research Conference

描述(由申请人提供)： 这项申请征集了NIH的资金，以部分支持定于2月21-26日在加利福尼亚州文图拉举行的2010年戈登血管紧张素研究会议。这次会议将召集150名肾素-血管紧张素系统(RAS)领域的领先和新兴科学家，进行为期5天的会议，包括12次口头会议(约40名发言者)和两次晚间海报会议。会议的主要目标是：1)提供一个论坛，传播有关血管紧张素在健康和疾病中作用的分子基础的未发表数据；2)促进基础和临床研究人员之间坦率和不受限制的互动，为新的和更好的治疗方法提供基础。该计划包括详细介绍基于血管紧张素的疗法的开发和最新应用的会议-从偶然发现蛇毒中的ACE抑制剂，到AT1受体阻滞剂、肾素抑制剂、AT2受体激动剂、重组ACE2疗法以及使用血管紧张素疫苗的最新临床试验。所有会议都旨在将分子/机械洞察力与翻译/临床数据结合起来，涵盖从高血压、心力衰竭和动脉瘤到纤维化、炎症和糖尿病并发症等与血管紧张素相关的各种病理。特别令人感兴趣的会议将详细介绍机械拉伸和自身抗体激活血管紧张素受体的新数据，血管紧张素在血管发育、造血和ES细胞多能性中的新作用，以及侧重于RAS基因类型和修饰因子在健康和疾病中的遗传学会议。作为专门为RAS服务的首屈一指的会议，戈登血管紧张素研究会议有着悠久的传统，展示了与国家心肺和血液研究所的使命直接相关的最重要的分子进展和临床见解。与公共健康相关：我们产生一种名为血管紧张素的荷尔蒙，它会升高血压，并在我们的体内保留液体和盐分。太多的血管紧张素会导致高血压和心脏、肾脏和血管疾病，这在我们的社区中是导致过早死亡的重要原因。对血管紧张素作用的研究继续为治疗心血管疾病患者提供新的途径，从而延长生命和提高生命质量。

DESCRIPTION (provided by applicant): This application solicits NIH funding to partially support the 2010 Gordon Research Conference on Angiotensin scheduled for February 21-26 in Ventura, California. The conference will assemble 150 leading and emerging scientists in the renin-angiotensin system (RAS) field for a 5-day meeting, involving 12 oral sessions (with ~40 speakers) and two evening poster sessions. The primary goals of the conference are: 1) to provide a forum for disseminating unpublished data on the molecular basis of angiotensin actions in health and disease, and 2) to facilitate candid and unrestricted interaction between basic and clinical researchers, providing a foundation for new and better therapeutic approaches. The program includes sessions detailing the development and latest application of angiotensin-based therapies - from the serendipitous identification of ACE inhibitors in snake venom, through AT1 receptor blockers, renin inhibitors, AT2 receptor agonists, recombinant ACE2 therapies as well as the latest clinical trials using angiotensin vaccines. All sessions have been designed to incorporate molecular/mechanistic insights with translational/clinical data and cover the gamut of angiotensin-related pathologies from hypertension, heart failure and aneurysms to fibrosis, inflammation and diabetic complications. Of particular interest will be sessions detailing new data on the activation of angiotensin receptors by mechanical stretch and autoantibodies, the novel role of angiotensin in blood vessel development, hematopoiesis and ES cell pluripotency, and a genetics session focused on RAS genotypes and modifiers in health and disease. As the premier meeting catering exclusively for the RAS, the Gordon Research Conference on Angiotensin has a long tradition of revealing the most important molecular advances and clinical insights that are directly relevant to the mission of the National Heart, Lung and Blood Institute. PUBLIC HEALTH RELEVANCE: We produce a hormone called angiotensin, which raises blood pressure and retains fluids and salts in our bodies. Too much angiotensin causes high blood pressure and diseases of the heart, kidneys and blood vessels, which contribute significantly to early death in our communities. Research into the actions of angiotensin continues to provide new avenues for treating patients with cardiovascular disease, thereby prolonging life and its quality.